Non-Invasive Prenatal Testing (NIPT)

Non-Invasive Prenatal Testing (NIPT)

Abstract

The life science industry is focused on the development of advanced NIPT tests using genome sequencing technologies for the early detection of genetic disorders. The increasing prevalence of genetic disorders and development of the healthcare infrastructure are promoting the adoption of the NIPT for better diagnosis and improved prenatal care.

What is NIPT

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. It is a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cff-DNA) in the maternal plasma. The genetic screening is performed between 10-22 weeks of time frame, with small amount of blood sample and requires a minimum of 10 weeks of pregnancy for apt results.

NIPT is commercializing at a rapid pace due to emerging technologies for non-invasive analysis of the fetal genome, thus reducing the cost-effectiveness of NIPT. The exponential growth of the NIPT market is supported by various factors, such as reimbursement policies, insurance coverage, high incidence rate of Down syndrome, no risk of miscarriage with NIPT, and shifting trend toward child birth at an advanced maternal age (35 years or above).Currently, NIPT is considered as a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders.

Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders.

The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products.

Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.

Brief Market Analysis

Since the past few years (2011-2017), prenatal genetic testing has come up with new innovative and non-invasive technologies and testing options. However, it has been a challenge for women's healthcare providers to keep up with the swarm of publications and provide patients with the most accurate information regarding prenatal testing. Since a decade, researchers, physicians, and even pregnant women have been observing the benefits of a non-invasive tests that could potentially replace amniocentesis and chorionic villus sampling (CVS), and minimize the false positive results generated by them. Hence, with the advent of NIPT, there has been a reduction in the number of women undergoing highly invasive procedures.

With the increasing demand for technological advancements in NIPT across various segments of the NIPT, the NIPT market is expected to witness rapid growth in the future. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. is the key driver for the growth of the NIPT market. Moreover, the Panorama test dominated the global NIPT market in 2017 among different commercialized tests. However, the IONA test is anticipated to witness the highest CAGR during the forecast period. The trisomy detection application of NIPT witnessed the highest industry demand. Further, the NGS platform for NIPT is also expected to witness impressive CAGR during the forecast period.

On the basis of regions, the global NIPT market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global NIPT market and contributed 51.55% and 52.31% in terms of revenue and volume respectively to the global market in 2017. However, Asia-Pacific is expected to grow at a CAGR of 18.01% and 19.13% in terms of revenue and volume respectively during the forecast period.The global NIPT market is expected to reach $5.67 billion with 7,591,792 units by 2028.

Please feel free to contact us via info@weiyunbio.com